newsfilter
← Latest News
GlobeNewswire·

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially